All In MedTech

Device Trial Radar · NCT07143019

The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms

p48/64 MW HPC in Aneurysm Occlusion (PIANO): Prospective, Multicenter, Single-arm Clinical Trial to Determine Safety and Effectiveness of the Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms.

Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

214

Planned (sponsor's estimate)

Start

Mar 16, 2026

Primary completion

Jul 2027

Study completion Jul 2032

Sponsor

Lead sponsor
phenox Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
Phenox GmbH
First posted
Aug 27, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine safety and effectiveness of the p48 MW HPC and p64 MW HPC Flow Modulation Device in the treatment of wide-necked intracranial aneurysms.

Conditions

  • Hemorrhagic Stroke
  • Aneurysm, Intracranial
  • Saccular Aneurysm
  • Fusiform Aneurysm
  • Brain Aneurysm

Interventions

  • Flow diversionDevice

    The p48 MW HPC and p64 MW HPC Flow Modulation Device is indicated for use in the treatment of intracranial aneurysms (IAs) arising from a parent vessel with a diameter of ≥2.0mm and ≤5.0 mm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Efficacy and Performance Endpoint: Number of subjects with 100% occlusion of the target aneurysm without significant parent artery stenosis and no retreatment of the target aneurysm from the index procedure to the 12-month follow-up visit.Time frame: 12 months
  2. The Primary Safety Endpoint: Number of subjects with ischemic or hemorrhagic stroke or neurologic death from treatment to 12-months, as adjudicated by a Clinical Events Committee.Time frame: From treatment - 12 months

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Barrow Neurological Institute

    Phoenix, Arizona · Recruiting

  • University of Southern California Health Sciences / Keck Hospital of USC

    Los Angeles, California · Recruiting

  • UCSF Medical Center

    San Francisco, California · Recruiting

22 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.